• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

German medics report on drug success for Ebola patient

Bioengineer by Bioengineer
December 19, 2014
in Health, Microbiology
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

German doctors on Friday gave details of how an experimental drug together with advanced intensive care helped save a Ugandan physician who had been airlifted from Sierra Leone with Ebola.

German medics report on drug success for Ebola patient

A scanning electron micrograph of Ebola virus budding from a cell (African green monkey kidney epithelial cell line). Photo Credit: NIAID

A prototype drug called FX06, designed to stop haemorrhage, was given to the patient after the doctors got special authorisation from their hospital’s ethics committee, they reported in The Lancet.
“Even though the patient was critically ill, we were able to support him long enough for his body to start antibody production and for the virus to be cleared by his body’s defences,” said Timo Wolf of University Hospital Frankfurt.

The Frankfurt team and the makers of the experimental drug had announced its use in early November.
Publication in The Lancet, a leading peer-reviewed medical journal, validates this announcement.
The unnamed 38-year-old male doctor had been airlifted to Frankfurt in early October, five days after the onset of Ebola symptoms, and admitted to a Biosafety 4 facility, the highest level of medical security, the study said.

Within three days of admission, he was suffering from failure of the lungs, kidneys and gastro-intestinal tract, as well as haemorrhaging blood vessels, a hallmark of Ebola infection.
He was placed on a ventilator and kidney dialysis and administered with antibiotics and a three-day course of FX06.

Called a fibrin-derived peptide, FX06 is designed to seal off the walls of blood vessels, which become permeable when infected by a haemorrhagic virus.

The peptide works by binding to the surface of endothelial cells, which form the inner cell layer of blood vessels. It latches onto the cells via a target called VE-cadherin.
The drug was invented at Vienna General Hospital and is made by a small Austrian firm called MChE-F4Pharma.

It had previously been tested on lab mice infected with the dengue virus and was also put through a trial among 234 European patients to assess its potential for limiting damage to cardiac tissue after a heart attack.

The combination of intensive care and the drug helped the Ugandan patient to stabilise and then recover, the doctors reported.

After a 30-day observation period, no trace of Ebola was found in his blood, and he was released from hospital to return to his family.

But the Lancet study also reported that shortly after this case, another Ebola patient with acute Ebola and haemorrhage was treated with FX06 at a hospital in the eastern Germany city of Leipzig, but died.
Treating Ebola cases in intensive care is a task with “complexity and specific challenges,” it warned.
FX06 is “a potentially valuable therapeutic candidate” for fighting the disease, the authors said, calling for the drug to be assessed in clinical trials.

More than 6,900 people have died in the latest Ebola epidemic, which is centred on the west African states of Guinea, Liberia and Sierra Leone, the World Health Organization (WHO) said on Wednesday.

Story Source:

The above story is based on materials provided by The Lancet.

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Whole-Body Vibration Training Reduces Body Mass: Review

August 22, 2025
blank

Ahead of Print: The Journal of Nuclear Medicine Tips – August 22, 2025

August 22, 2025

Childhood Obesity Linked to Adult Gallstones, Shared Genes

August 22, 2025

Biomimetic Magnetobots Revolutionize Pneumonia Treatment

August 22, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Whole-Body Vibration Training Reduces Body Mass: Review

Study Finds Speed Isn’t Everything in Covalent Inhibitor Drug Development

Shaping the Future of Dysphagia Diets Through 3D Printing Innovations

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.